Post by
christopher707 on Mar 14, 2024 8:22am
Bioxytran's Innovative Approach to Drug Design
Bioxytran, Inc. ($BIXT) pioneers novel carbohydrate structures using AI to create rational drug designs. With a market cap of $19.53 million and 165.58 million outstanding shares, their leading antiviral candidate, Prolectin-M, targets galectins implicated in inflammatory diseases. The 30-day average volume is 78,867, highlighting growing interest in their transformative solutions.